A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. (June 2017)

• Record Type: Journal Article
• Authors: Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P.M.; Batlevi, C.L.; Chen, R.; Constine, L.S.; Courtien, A.I.; Dandapani, S.V.; Drullinsky, P.; Friedberg, J.W.; Hamlin, P.A.; Hoppe, R.T.; Matasar, M.J.; McArthur, G.N.; Miller, S.T.; Moskowitz, A.J.; Noy, A.; Schoder, H.; Straus, D.J.; Yang, J.; Younes, A.; Zelenetz, A.D.; Yahalom, J.; Moskowitz, C.H.
• Is Part Of: Hematological oncology. Volume 35(2017)Supplement 2
• Page Start: 171
• Page End: 172
• Publication Date: 2017-06
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2438_30
• Languages: English
• ISSNs: 0278-0232